PAK2

Across TCGA pan-cancer cohorts, PAK2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAK2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PAK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where PAK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.541	0.885	<.001	60	view →
HNSC	OS	Tertile	IV	0.533	0.840	.005	4	view →
LUAD	DFS	Tertile	All	0.994	0.909	.047	3	view →
PDAC	OS	Quartile	III,IV	0.423	0.988	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PAK2–CCRCC (DFS)

Open the CCRCC breakdown →